"Since joining Panakes Partners in 2021, Andrea is supporting the venture capital team across deal sourcing, due diligence, and strategic investment in new therapeutics. His work includes in-depth technology, market, and competitive analysis, as well as a focus on assessing unmet medical needs. Andrea brings experience in pharmacology and drug development, both in preclinical and clinical research, plus expertise in nanotechnology design and development refined during his postdoctoral fellowship at the Houston Methodist Research Institute. Prior to Panakes, he served as a project manager at BiovelocITA, a leading biotech accelerator supported by Sofinnova Partners, where he focused on seed funding groundbreaking innovations developed by Italian scientists. Education MD, University of Milan (Doctor of Medicine) Fellowship in Clinical Pharmacology and Toxicology, University of Mila"

"Roberto is an investor in the biotech space, with +15 years of investing experience spanning from early stage to private equity deals across multiple geographies. He serves on the Board of multiple life-science companies throughout Europe and the US, including Vasopharm GmbH (Germany, traumatic brain injury), GNS Healthcare (Cambridge, digital health), Medinet (UK, outsourcing services). Roberto was a member of 3i’s Private Equity team in London and Milan, investing across sectors but with a particular focus on healthcare. He was previously based in New York with the international merchant bank Greenhill & Co. Roberto graduated cum laude from Università Bocconi (Milan, Italy) and holds an MBA with honors from The Wharton School of the University of Pennsylvania."

"Since 2010, Paolo is CEO of GDS Communication, a communication and marketing agency in the Healthcare sector, which joined ” The European House Ambrosetti ” in April 2023. He is Principal Expert and Member of the Development Committee of “The European House Ambrosetti “. Since 2022 he is President of Confindustria Giovani di Como and Vice President of Confindustria Como. Since 2023 he is part of the “Rotary Club Como” and “Amici di Como”. He graduated in Economics from Università Cattolica del Sacro Cuore and in Marketing from the SGH Warsaw School of Economics. He holds certifications in Budgeting and Controlling and in New Digital Communication from the 24h Business School, in Business Accounting from «Chartered Institute of Management Accountants” and in Value-Based medtech: How to Succeed in a Challenging Environment from SDA Bocconi. Previously, Paolo has worked for international companies such as Alcon, Carat and Accenture."

"Founder of BluPhytal, a company which, trough its Rare Insight Consulting division, supports healthcare companies to develop their presence in the Orphan Disease arena. Co-founder of BlueDil International, wich serves as virtual affiliate for Pharma Companies in Europe, providing a cost-effective approach establishing and expanding business in the market of rare disease orphan drugs across Europe and beyond. From 2016 to 2019 Leonardo has served as Head of Global Rare Diseases Franchise at Chiesi, managing the Strategic Marketing process and supporting Business Development activities. From 2008 to 2015 Leonardo has created and developed the Italian affiliate of Swedish Orphan Biovitrum (SOBI), managing also Greece and Malta territories. In this role Leonardo has represented SOBI into Assobiotec (Italian Association for the Development of Biotechnologies) becoming member of the directive board. Previously has spent 20 years in pharma business in positions with increasing responsibility in operational and strategic marketing, mainly in rare or severe diseases."

"Danilo is a serial entrepreneur and investor in the Health Care and Biotech space with over 40 years of experience. Founder of several start-ups in multiple geographies with a track record of successful exits. Chairman and Founder at Nemysis Ltd, an Irish Biotech company, Director at One-Bio in California. Recently Founder of The European Healthcare Alliance, a cross-licencing network, and of Feeding Ideas, an early stage investment entity. Independent Member of the Health Care Investment Committee at Seventure, France Danilo has served as Senior Executive in Pharma companies in Italy, USA, France, Germany, Ireland, Switzerland, Colombia and the UK Considerable experience in the “grey area” between food and pharma with a thorough understanding of the Regulatory environment."

Alessandro Crevani has been the General Manager of General Medicine at Sanofi Italy and Malta since 2021. Born in Pavia in September 1973, he graduated in Pharmacy with a focus on Oncology and Hospital Pharmacy studies from the University of Pavia. With a career spanning over two decades, Alessandro has demonstrated exceptional skills in managing and developing corporate strategies, marketing strategies, market access, sales, medical affairs, and excelling in product launches at both national and global levels in the fields of oncology, immunology, hematology, urology, cardiovascular, and metabolic disorders. Throughout his extensive career, Alessandro has held various roles of increasing responsibility at national and international levels in leading global biopharmaceutical companies, including Schering Plough, Sanofi, and Sanofi Genzyme. His dedication and expertise have led him to significant roles within different departments of Sanofi, where he has made substantial contributions to the access and launch of major innovative biologic therapies in Italy. Alessandro is passionate about healthcare modernization, digital health, artificial intelligence, and all innovations that impact public health. He firmly believes in the social value of the pharmaceutical industry and its employees in creating a positive impact on the community. His leadership has been pivotal in the creation and development of Sanofi's Immunology Franchise, positioning the company as a leader in the sector. Outside of work, Alessandro enjoys running, cycling, and off-road competitions. He is fluent in English and French, in addition to his native Italian.

"Fabrizio is the founder and CEO of Valere, an independent financial advisory house focused on healthcare (www.valereadvisory.com) He has almost 30 years’ international experience in Corporate Finance, with main focus on M&A, coupled with a deep knowledge of Equity Capital Markets, Private Equity, Debt Advisory, Turnaround, Valuation and Business Modeling Fabrizio has a wealth of international transaction experience, having worked on over 100 transactions (mostly cross-border) worth in excess of €25bn In the last ten years he has served as advisor on more than 40 Pharma / Healthcare corporate finance projects for Private Equity funds and corporate clients In addition, he has extensive management experience as a key contributor in the start-up of four corporate finance teams in three different organizations Before founding Valere, Fabrizio used to run the Italian Life Sciences practice at EY (which he started up) from 2015 to 2021 Before joining EY in 2012, Fabrizio co-founded and developed for four years DVR Capital, a successful start-up independent merchant bank (2008-2012); prior to that, he has worked for ten years at the Investment Banking Division of Salomon Smith Barney / Citi in London, Sydney and Milan (1998-2008) Graduated with Honors in Business Law in 1998 at the Bocconi University in Milan, Fabrizio is a native speaker of Italian, is fluent in English and French and has a working knowledge of Spanish"

"Serena holds a P.h.D degree in Molecular/Cellular Biology and is a passionate scientist with over 30 years of experience. Owner of B&F BioConsulting company. Staff scientist at the biotechnology unit at Dibit-HSR for 13 years. Her research activities have been devoted to understanding basic cellular mechanisms in plant and human cell biology using also targeted recombinant plant toxins in applied Experimental Oncology, as documented by more than 40 articles published in leading international scientific journals. She led as PI & Coordinator a 5-year collaborative research study “Recombinant Immunotoxin Cooperation Group” (RICG) supported by “Leukaemiabusters”, UK. She authored more than 40 papers in international journals and worked independently for several years in scientific Consultancy as Telethon grant scientific manager, INGM scientific officer at Policlinico Milano, as a medical/scientific writer. She has gained extensive scientific experience managing several hundred national grant applications reviewing for International Funding Agencies (UK, India, Singapore), and writing scientific grant proposals (AIRC, CNR, ERC, EIC). Reviewer for several international biomedical journals and editor for Frontiers “Experimental Pharmacology and Drug Discovery” since 2020."

"Laura is Panakes Fund Executive Advisor (biomedical technologies and medical devices) She is President of Bio4Dreams, the first entirely privately owned business nursery in life sciences in Italy. She is Board Member of Molmed S.p.A., listed on the Milan Stock Exchange. She is Board Member of several startups: Newronika, BrainDTech and Wise. She is Board Member of Sorin Group and actively engaged in another business angels association, Italian Angels for Growth She got her MD at University of Milan and then her PhD both in Psychiatry and Clinical Pharmacology at the same University. She got also a MBA Master (evening session) at Milan’s Bocconi University Psychiatrist in different public structures. She has covered different roles, including Director of Research and Managing Director, in Pharmaceutical Company Crinos SpA (from 2002 Sirton pharmaceuticals SpA). She has been Chairman of Foltene Laboratories (hair care products). The Company has been re-launched and then ceased. She was also Managing Director of Sirton Pharmaceuticals, B- to-B drugs manufacturing Company. Laura founded Gentium Spa, of which she has been Managing Director. She has developed Company’s assets managing the listing on USA capital markets, first at Amex and then at Nasdaq. The Company then was sold to Jazz Pharmaceuticals. She was Chairman of Azienda di Servizi alla Persona Istituti Milanesi Martinitt e Pio Albergo Trivulzio (largest geriatric hospital and nursing home in Italy). She is President of Bio4Dreams, the first entirely privately owned business nursery in life sciences in Italy. She is Board Member of Molmed S.p.A., listed on the Milan Stock Exchange. She is Board Member of several startups: Newronika, BrainDTech and Wise."

"Marco is co-founder of the Swiss based investment firm Continental Investment Partners, of which is one of the two Managing Partners. Marco has a 15 years significant transaction track-record as a Global Partner at the Private Equity house 3i Group, with significant results in the management of investments in both private (Giochi Preziosi, Coelsanus Preserves, Vis Pharmaceuticals, Newron) and listed companies (Biosearch Italy, Datamat, Novuspharma). In 2010 he became the Head of the Private Equity at Swiss family office Leponte SA and during 2012 he led the public to private takeover of Corin Group plc, an orthopaedic implants company then listed in London."

"Roberto is Vice President Finance at Newron Pharmaceuticals since 2012. He joined Newron in 2002. Since, he has covered various managerial positions within the Finance Department and has been involved in the IPO, secondary fund raising, M&A and other strategic corporate transactions. He started as auditor at Coopers&Lybrand (CL), before joining PricewaterhouseCoopers (PwC) where he served as Senior Auditor & Business Advisor dealing with companies from the pharmaceutical, fashion, energy and automotive industries. He has more than 18 years of experience in biotech, finance and auditing. He holds a degree in Business Economics from the University Luigi Bocconi in Milan and he is registered with the national register of auditors. Roberto has extensive international accounting, controlling and tax experience overseeing Newron group subsidiaries based in Sweden, Switzerland, USA and UK."

"Luca is the co-founder of STUDIO LEGALE GARIBALDI-QUARZO, a Milan-based law firm specializing in corporate, commercial and idustrial law applied, principally, to the Health sector. Prior to professing as a self-employed lawyer, he matured a significat experience as head of legal affairs in a leading international medical device company, contributing to the implementation of the primary EU directives on Medical Devices . Since 1999, as a Milan-listed business lawyer, he has continued to practice law with special focus in the fields of pharmaceutical law and, more generally, of the laws that form the operational-basis for any company active in the health sector. Luca continues to act as general counsel for a selected number of leading national and international companies operating in his fields of practice and expertise. He has assisted several entrapeneurs, both inventors and investors, through the various stages of their business-ventures, until maturity and full expansion of their businesses, including cases of reknown all-Italian success. In his more than ventennal experience in the health sector, Luca has also managed to distinguish himself as one of the few lawyers with an in-depth knowledge of the laws and regulations applicable to clinical-trails on medicinal products for human use. He also continues to practice corporate and commercial law for ordinary and non-ordinary operations, with a clear inhouse-like approach which is both practical and informal."